TIRmed Pharma, a biotechnology company developing next-generation treatments for autoimmune skin diseases, has entered into a collaboration with Bachem, a leading company in advanced oligonucleotide manufacturing. The collaboration covers process development and manufacturing of TIR-01, the active pharmaceutical ingredient in TIRmed’s novel therapy for atopic dermatitis (eczema). This marks an important step toward upcoming clinical trials.
TIRmed Pharma is advancing a next-generation treatment for atopic dermatitis, designed to offer patients effective treatment with fewer side effects and simpler administration. The treatment targets the root causes of the disease rather than merely alleviating symptoms. In preclinical studies, five topical applications over two weeks have resulted in up to 15 months of sustained relief.
As part of its preclinical program, TIRmed Pharma has partnered with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based substance. With its expertise in oligonucleotide manufacturing, Bachem contributes essential capabilities for GMP development, ensuring stability, consistency, and regulatory compliance ahead of clinical trials.
"The work with Bachem is an important milestone in our work to advance our candidate drug to the clinic. Through this collaboration, we gain access to world-leading manufacturing expertise and strengthen the foundation for offering patients a more durable treatment option," says Leo Holmgren, CEO of TIRmed Pharma.